Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial
Mitsuaki Sawano, Bornali Bhattacharjee, César Caraballo, Rohan Khera, Shu Xia Li, Jeph Herrin, Dany Christian, Andreas Coppi, Frederick Warner, Julie Holub, Yashira Henriquez, Maria A. Johnson, Theresa B. Goddard, Erica Rocco, Amy C. Hummel, Mohammad AL Mouslmani, William Brenham Hooper, David F. Putrino, Kevin D. Carr, Lawrence CharnasMagdia De Jesus, Dale Nepert, Paula Abreu, Frank W. Ziegler, John A. Spertus, Akiko Iwasaki, Harlan M. Krumholz
Research output: Contribution to journal › Article › peer-review
9Scopus
citations
Fingerprint
Dive into the research topics of 'Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial'. Together they form a unique fingerprint.